8H0I image
Entry Detail
PDB ID:
8H0I
EMDB ID:
Title:
Cryo-EM structure of APOBEC3G-Vif complex
Biological Source:
PDB Version:
Deposition Date:
2022-09-29
Release Date:
2023-07-19
Method Details:
Experimental Method:
Resolution:
2.80 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:APOBEC3G
Chain IDs:A, B
Chain Length:371
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Viral infectivity factor
Chain IDs:C, E, G, I
Chain Length:152
Number of Molecules:4
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:Core binding factor beta
Chain IDs:D, F, H, J
Chain Length:156
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polyribonucleotide
Description:RNA (5'-R(*CP*GP*GP*UP*UP*GP*AP*UP*CP*GP*UP*UP*UP*UP*AP*AP*CP*AP*A)-3')
Chain IDs:K (auth: X), L (auth: Y)
Chain Length:20
Number of Molecules:2
Biological Source:synthetic construct
Primary Citation
Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.
Nat Commun 14 4037 4037 (2023)
PMID: 37419875 DOI: 10.1038/s41467-023-39796-5

Abstact

Great effort has been devoted to discovering the basis of A3G-Vif interaction, the key event of HIV's counteraction mechanism to evade antiviral innate immune response. Here we show reconstitution of the A3G-Vif complex and subsequent A3G ubiquitination in vitro and report the cryo-EM structure of the A3G-Vif complex at 2.8 Å resolution using solubility-enhanced variants of A3G and Vif. We present an atomic model of the A3G-Vif interface, which assembles via known amino acid determinants. This assembly is not achieved by protein-protein interaction alone, but also involves RNA. The cryo-EM structure and in vitro ubiquitination assays identify an adenine/guanine base preference for the interaction and a unique Vif-ribose contact. This establishes the biological significance of an RNA ligand. Further assessment of interactions between A3G, Vif, and RNA ligands show that the A3G-Vif assembly and subsequent ubiquitination can be controlled by amino acid mutations at the interface or by polynucleotide modification, suggesting that a specific chemical moiety would be a promising pharmacophore to inhibit the A3G-Vif interaction.

Legend

Protein

Chemical

Disease

Primary Citation of related structures